Alzheimer's Disease - The Puzzles, The Partners, The Path Forward
PhRMA, November 26, 2013
http://www.innovation.org/index.cfm/NewsCenter/Newsletters?NID=218
Alzheimer's is a
debilitating neurodegenerative disease that currently afflicts more than
5 million people in the U.S. If no new medicines are found to prevent,
delay or stop the progression of Alzheimer's disease, the number of
affected people in America will jump to 15 million by 2050 and related
healthcare costs could increase five-fold to $1.2 trillion, according to
the Alzheimer's Association. In contrast, a medicine that delays onset
of Alzheimer's disease by five years would lower the number of Americans
suffering from the disease by nearly half and save $447 billion in
related costs, in 2050.
America's biopharmaceutical companies are currently developing 73
potential new treatments and diagnostics for Alzheimer's, according to a
recent report released by PhRMA. At a recent all day-forum, "Alzheimer's: The Puzzle, The Partners, The Path Forward,"
the Alzheimer's Association, Alzheimer's Drug Discovery Foundation,
and PhRMA convened key stakeholders from the Alzheimer's community to
discuss these therapies presently in development to treat the disease,
as well as the current state of innovation and R&D for Alzheimer's
disease treatments and diagnostics.
Among the key areas of discussion were pre-competitive partnerships,
including potential areas for collaboration and public-private
partnerships, as well as pre-symptomatic clinical trials, which may help
researchers understand the clinical heterogeneity of the disease and
subsequent challenges in the use and adoption of clinical and functional
endpoints in new clinical trial design.
Panelists included top industry and academic scientists,
policymakers, patients, payers, and many others. Executives from the
Alzheimer's Association and Alzheimer's Drug Discovery Foundation also
discussed the path forward for Alzheimer's disease in relation to
science and policy.
Continue the conversation online using the event hashtag #ALZpov
No comments:
Post a Comment